# OTraces

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/otraces

- Industry: Healthcare Specialists
- Headquarters: Germantown, US
- Website: www.otraces.net
- Total disclosed funding: $0.1M
- Latest round: Series D (Sep 10, 2012)
- Investors on record: 1

## About

OTraces, Inc. specializes in advanced diagnostic solutions that leverage signal processing and machine learning technologies for early disease detection, offering a highly accurate diagnostic platform and services to enhance healthcare outcomes.OTraces focuses on the development of a diagnostic platform that achieves over 95% accuracy across various medical indications. The company is headquartered in Germantown, US. Founded by Alain Cappeluti and Keith Lingenfelter, OTraces has secured USD 0.08 mn in funding during its Series D round from TCP Venture Capital on September 10, 2012. The total amount raised by the company stands at USD 0.08 mn with a current valuation of USD 6.424 mn.OTraces offers a diagnostic platform specializing in early disease detection, deploying advanced signal processing and machine learning technologies. The platform is designed for accuracy exceeding 95%, aimed at developing precise diagnostic tests for conditions such as cancer and chronic diseases. Targeted clients include researchers and diagnostic test providers, with the company collaborating to integrate its technologies into existing workflows, thereby improving patient care outcomes. OTraces serves a global market, with clients in North America, Europe, and Asia.OTraces derives revenue from partnerships with diagnostic test providers and researchers through a subscription-based model for access to its high-accuracy diagnostic platform. Collaborations involve customizing solutions to meet specific diagnostic requirements, facilitating a B2B transaction structure. While specific pricing details are proprietary, the company’s offerings are classified as premium solutions within the healthcare diagnostics sector, catering to the growing demand for innovative diagnostic tools that support early detection and intervention.OTraces plans to utilize the funds from its recent Series D round to advance the development of new diagnostic products and expand into new markets. The company is targeting the European and Asian markets for growth by 2024. The funding will support the design and launch of enhanced diagnostic solutions, with an emphasis on integrating more advanced analytical capabilities into their existing platform.

## Funding rounds

- Series D, Sep 10, 2012, $0.1M — TCP Venture Capital

## Investors

- TCP Venture Capital (https://capitalatlas.ai/funds/tcp-venture-capital) — Series D